Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Healthy Element: The company is a potential leading domestic enterprise in the field of respiratory inhalation preparations.

Time Posted:2019-06-06 09:10

The company's wholly-owned subsidiary, Tai Tai Pharmaceutical, has obtained new GMP certification for its non-hormonal liquid inhalation solution production line. This allows for the production and sale of inhalation compound ipratropium bromide solution. Inhalation compound ipratropium bromide solution is the first domestically-produced generic, presenting a favorable competitive landscape.

Chronic Disease Poverty Alleviation: Follow-up Support and Warmth

Time Posted:2019-05-31 09:40

To thoroughly implement the Party Central Committee's requirements for targeted poverty alleviation, strengthen efforts in targeted poverty alleviation, and ensure that poverty alleviation work is carried out effectively, recently, a team of six volunteers from the Healthy Yuan Volunteer Association, assisted by the local government and a charity association, went to Songpan County, Aba Tibetan and Qiang Autonomous Prefecture, Sichuan Province, to conduct follow-up work on the Healthy Yuan & Lizhu Pharmaceutical Group chronic disease poverty alleviation project.

Following the news of "entering the market" and "entering the rich" (the rich GEIS index), Jiankangyuan & Lizhu Group received positive news.

Time Posted:2019-05-31 09:19

In the early morning of May 25, Beijing time, FTSE Russell, the world's second-largest index company, announced the first batch of A-shares to be included in its index system. This list includes large-cap, mid-cap, and small-cap stocks, with a total of 1097 A-shares selected, including Health and Medicine Group and Lizhu Group.

Jiankang Yuan Yi inhalation solution drug obtained registration approval

Time Posted:2019-05-29 11:03

Health Yuan announced on the evening of April 9 that its research drug, inhaled combined ipratropium bromide solution, has recently received the Drug Registration Certificate issued by the National Medical Products Administration. This drug, through the combined administration of ipratropium bromide and salbutamol sulfate, can simultaneously act on the muscarinic and β2-adrenergic receptors in the lungs, relaxing the smooth muscles of the respiratory tract from the main bronchi to the terminal bronchioles. It is suitable for patients who need the combined use of multiple bronchodilators, used to treat reversible bronchospasm related to airway obstructive diseases. Its efficacy is superior to single-drug administration, making it a clinical drug for patients with moderate to severe asthma and COPD. According to the announcement, as of that day, the total direct research and development costs for this drug were approximately 6.2384 million yuan. The announcement stated that currently, the only inhaled combined ipratropium bromide solution on the market in China is Boehringer Ingelheim's "Tiotropium Bromide." According to IQVIA data, the product's domestic sales in 2018 were approximately 343.44 million yuan. According to the website of the Center for Drug Evaluation of the National Medical Products Administration and the Xinda database, as of the date of the announcement, in addition to the original research product, only the company has obtained the registration certificate for this product. Another company has submitted a registration application for this product, which is currently under review and approval. (Huang Shu) Reprinted from: China Securities Journal

Jiankangyuan Group & Lizhu Group may be included in the MSCI index

Time Posted:2019-05-29 09:49

MSCI, a world-renowned index compiler, announced in the early hours of March 1, Beijing time, that it plans to significantly increase the weighting of Chinese A-shares in three steps. Information from the Shanghai Securities News, Zhuhai Special Zone News, and the MSCI website suggests that Health and Genesis Group & Lizhu Group are likely to be included in the MSCI China constituents.

The "Three Products" strategy shows results; Health Yuan's star product wins another award

Time Posted:2019-03-27 11:28

On March 15, the "Guangdong Pharmaceutical Industry Implementation of the Three-Product Strategy Achievements Conference and Association Annual Meeting" was held in Guangzhou. Relevant leaders, including Yan Zhen, Deputy Director of the Guangdong Drug Administration, attended the meeting. The meeting commended a number of outstanding enterprises that made outstanding contributions to the "Three-Product" strategy. Several traditional Chinese medicine products, including "Jingxin Oral Liquid" from Health Yuan Pharmaceutical Group, "Baoji Pill" from Guangzhou Wanglaoji Pharmaceutical, and "Wujibai Feng Pill" from Chen Li Ji Pharmaceutical Factory, won the title of "2018 Guangdong Pharmaceutical Industry Brand-Name Product".

< 1...484950...55 >